How do tumor stem cells actively escape from host immunosurveillance?

Biochemical and Biophysical Research Communications

Volumn 420, Issue 4, 2012, Pages 699-703

  Qi, Yao ^a   Li, Run Mei ^a   Kong, Fan Ming ^a   Li, Hui ^a   Yu, Jin Pu ^a   Ren, Xiu Bao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Immune escape; Microenvironment; Tumor stem cells; Tumorigenesis

Indexed keywords

BETA 2 MICROGLOBULIN; CALNEXIN; CALRETICULIN; CD200 ANTIGEN; CD44V ANTIGEN; CD47 ANTIGEN; CHAPERONE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GANGLIOSIDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; METALLOPROTEINASE; MSI1 PROTEIN; NESTIN; PROTEIN BCL XL; PROTEIN P57; TAPASIN; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANGIOGENESIS; ANTIGEN EXPRESSION; APOPTOSIS; ASTROCYTOMA; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; FLOW CYTOMETRY; GENE MUTATION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MELANOMA; MESENCHYME CELL; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC SURVEILLANCE; NEOPLASTIC STEM CELLS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84859878440     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.086     Document Type: Short Survey

References (60)

1. Lapidot T., Sirard C., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
2. Al Hajj M., Wicha M.S., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
3. Collins A.T., Berry P.A., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
4. Li C., Heidt D.G., et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
5. Ricci-Vitiani L., Lombardi D.G., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
6. Singh S.K., Clarke I.D., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
7. Jordan C.T., Guzman M.L. Cancer stem cells. N. Engl. J. Med. 2006, 355(12):1253-1261.
8. Yang Z.F., Ho D.W., et al. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
9. Guerry D.T., Alexander M.A., et al. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J. Clin. Invest. 1984, 73(1):267-271.
10. Aptsiauri N., Cabrera T., et al. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 2007, 601:123-131.
11. Schatton T., Frank M.H. Antitumor immunity and cancer stem cells. Ann. NY Acad. Sci. 2009, 1176:154-169.
12. + glioma cells: possible targets of immunotherapy. J. Neuro Oncol. 2007, 83(2):121-131.
13. Di Tomaso T., Mazzoleni S., et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 2010, 16:800-813.
14. Pandha A., Rigg A., et al. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cell lines. Clin. Exp. Immunol. 2007, 148:127-135.
15. Johnsen A., France J., et al. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex tumor cell lines. Cancer Res. 1998, 58:3660-3667.
16. Rosenberg S.A., Restifo N.P., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8(4):299-308.
17. Dancescu M., Rubio-Trujillo M., et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J. Exp. Med. 1992, 176:1319-1326.
18. Conticello C., Pedini F., et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J. Immunol. 2004, 172:5467-5477.
19. Todaro M., Alea P.M., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1(4):389-402.
20. Trapani J.A., Sutton V.R. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 2003, 15:533-543.
21. Sabbagh M.K., Ifergan Igal, et al. Human glioblastoma cancer stem cells promote intra-tumoral immune regulatory functions. Clin. Immunol. 2009, 131(1):38.
22. Ahmadzadeh M., Felipe-Silva A., et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008, 112(13):4953-4960.
23. Clark R.A., Huang S.J., et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 2008, 205(10):2221-2234.
24. Shipitsin M., Campbell L.L., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11(3):259-273.
25. Piccirillo S.G., Reynolds B.A., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444(7120):761-765.
26. Schatton T., Murphy G.F., et al. Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-349.
27. + regulatory T cells. J. Immunol. 2006, 177(2):896-904.
28. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 2001, 7:1118-1122.
29. Jaiswal S., Jaieson C.H., et al. CD 47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138(2):271-285.
30. Barclay A.N., Brown M.H. The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 2006, 6(6):457-464.
31. Majeti R., Chao M.P., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138(2):286-299.
32. Colonna M., Trinchieri G. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
33. Kawasaki T.B., Mistree T., et al. Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 2007, 364:778-782.
34. Barclay A.N., Wright G.J., et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002, 23:285-290.
35. Curiel T.J., Coukos G., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
36. Kretz-Rommel Anke, Qin Fenghua, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 2007, 178:5595-5605.
37. T.P. Rygiel, G. Karnam, et al., CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor, 2011, p. 10 (Epub ahead of print).
38. Yao J., Zhang T., et al. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol. Rep. 2009, 22(4):781-787.
39. Jianfei J.P., Keith L.B. Glioma stem cell research for the development of immunotherapy. Neurosurg. Clin. N. Am. 2010, 21(1):159-166.
40. + cancer stem cells in glioblasoma. Mol. Cancer 2006, 5:67.
41. Sneddon J.B., Zhen H.H., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2006, 103(40):14842-14847.
42. Taieb N., Maresca M., et al. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglio-side-binding motif. Cancer Lett. 2009, 278(2):164-173.
43. Shen W., Stone K., et al. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J. Immunol. 2008, 180(7):4425-4432.
44. Janes S.M., Watt F.M. New roles for integrins in squamous-cell carcinoma. Nat. Rev. Cancer 2006, 6(3):175-183.
45. Grzesiak J.J., Ho J.C., et al. The integrin-extracellular matrix axis in pancreatic cancer. Pancreas 2007, 35(4):293-301.
46. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5(15):1597-1601.
47. Dong M., Blobe G.C. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006, 107(12):4589-4596.
48. Overall C.M., Kleifeld O. Tumor microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6(3):227-239.
49. Liu J., Lu X.F., et al. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant. Proc. 2004, 36(10):3272-3275.
50. Taylor A., Verhagen J., et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006, 117(4):433-442.
51. Di Ianni, Del Papa, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol. 2008, 36(3):309-318.
52. Djouad F., Plence P., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102(10):3837-3844.
53. Calabrese C., Poppleton H., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11(1):69-82.
54. Hatfield K., Ryningen A. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119(10):2313-2321.
55. - cells through SDF-1/CXCR4 interaction. J. Exp. Clin. Cancer Res. 2010, 29(80).
56. Postovit L.M., Abbott D.E., et al. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. Cell Biochem. 2008, 103:1369-1378.
57. Li Z.Z., Bao S.P., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
58. Zhao Y., Bao Q., et al. Cancer stem cells and angiogenesis. Semin. Cancer Biol. 2009, 19(4):279-284.
59. Jin L., Hope K., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12(10):1167-1174.
60. Ohno R., Asou N. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17(8):1454-1463.